Elicera Therapeutics AB (publ) (FRA:8E8)

Germany flag Germany · Delayed Price · Currency is EUR
0.584
0.00 (0.00%)
Last updated: Dec 4, 2025, 8:02 AM CET
337.45%
Market Cap 29.33M
Revenue (ttm) 1.24M
Net Income (ttm) -1.18M
Shares Out n/a
EPS (ttm) -0.03
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Average Volume n/a
Open 0.584
Previous Close 0.584
Day's Range 0.584 - 0.584
52-Week Range 0.110 - 0.686
Beta n/a
RSI 64.47
Earnings Date Feb 13, 2026

About Elicera Therapeutics AB

Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2014
Employees 2
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 8E8
Full Company Profile

Financial Performance

In 2024, Elicera Therapeutics AB's revenue was 7.13 million, a decrease of -36.52% compared to the previous year's 11.23 million. Losses were -16.11 million, -1.75% less than in 2023.

Financial numbers in SEK Financial Statements

News

There is no news available yet.